Nucleostemin prevents telomere damage by promoting PML-IV recruitment to SUMOylated TRF1

Journal of Cell Biology

Volumn 197, Issue 5, 2012, Pages 613-624

  Hsu, Joseph K ^a   Lin, Tao ^a   Tsai, Robert Y L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; NUCLEOSTEMIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RAD51 PROTEIN; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; UNCLASSIFIED DRUG;

ALTERNATIVE LENGTHENING OF TELOMERE ASSOCIATED PROMYELOCYTIC LEUKEMIA BODY; ALTERNATIVE LENGTHENING OF TELOMERE CELL; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; DEPLETION; DNA DAMAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; SUMOYLATION; TELOMERASE ACTIVE CELL; TELOMERE;

GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; NUCLEAR PROTEINS; SUMOYLATION; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 1;

EID: 84862630360     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201109038     Document Type: Article

References (47)

1. Baddoo, M., K. Hill, R. Wilkinson, D. Gaupp, C. Hughes, G.C. Kopen, and D.G. Phinney. 2003. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J. Cell. Biochem. 89:1235-1249. http://dx.doi.org/10.1002/jcb.10594
2. Beekman, C., M. Nichane, S. De Clercq, M. Maetens, T. Floss, W. Wurst, E. Bellefroid, and J.C. Marine. 2006. Evolutionarily conserved role of nucleostemin: controlling proliferation of stem/progenitor cells during early vertebrate development. Mol. Cell. Biol. 26:9291-9301. http://dx.doi.org/10.1128/MCB.01183-06
3. Bryan, T.M., A. Englezou, J. Gupta, S. Bacchetti, and R.R. Reddel. 1995. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14:4240-4248.
4. Bryan, T.M., A. Englezou, L. Dalla-Pozza, M.A. Dunham, and R.R. Reddel. 1997. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 3:1271-1274. http://dx.doi.org/10.1038/nm1197-1271
5. Carneiro, T., L. Khair, C.C. Reis, V. Borges, B.A. Moser, T.M. Nakamura, and M.G. Ferreira. 2010. Telomeres avoid end detection by severing the checkpoint signal transduction pathway. Nature. 467:228-232. http://dx.doi.org/10.1038/nature09353
6. Carter, S., O. Bischof, A. Dejean, and K.H. Vousden. 2007. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9:428-435. http://dx.doi.org/10.1038/ncb1562
7. de Lange, T. 2005. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19:2100-2110. http://dx.doi.org/10.1101/gad.1346005
8. Dunham, M.A., A.A. Neumann, C.L. Fasching, and R.R. Reddel. 2000. Telomere maintenance by recombination in human cells. Nat. Genet. 26:447-450. http://dx.doi.org/10.1038/82586
9. Fasching, C.L., A.A. Neumann, A. Muntoni, T.R. Yeager, and R.R. Reddel. 2007. DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. Cancer Res. 67:7072-7077. http://dx.doi.org/10.1158/0008-5472.CAN-07-1556
10. Greider, C.W., and E.H. Blackburn. 1985. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 43:405-413. http://dx.doi.org/10.1016/0092-8674(85)90170-9
11. Greider, C.W., and E.H. Blackburn. 1989. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature. 337:331-337. http://dx.doi.org/10.1038/337331a0
12. Greider, C.W., and E.H. Blackburn. 1996. Telomeres, telomerase and cancer. Sci. Am. 274:92-97. http://dx.doi.org/10.1038/scientificamerican0296-92
13. Grobelny, J.V., A.K. Godwin, and D. Broccoli. 2000. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J. Cell Sci. 113:4577-4585.
14. Jensen, K., C. Shiels, and P.S. Freemont. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 20:7223-7233. http://dx.doi.org/10.1038/sj.onc.1204765
15. Jiang, W.Q., Z.H. Zhong, J.D. Henson, and R.R. Reddel. 2007. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene. 26:4635-4647. http://dx.doi.org/10.1038/sj.onc.1210260
16. Kang, M.R., M.T. Muller, and I.K. Chung. 2004. Telomeric DNA damage by topoisomerase I. A possible mechanism for cell killing by camptothecin. J. Biol. Chem. 279:12535-12541. http://dx.doi.org/10.1074/jbc.M309779200
17. Kibe, T., K. Tomita, A. Matsuura, D. Izawa, T. Kodaira, T. Ushimaru, M. Uritani, and M. Ueno. 2003. Fission yeast Rhp51 is required for the maintenance of telomere structure in the absence of the Ku heterodimer. Nucleic Acids Res. 31:5054-5063. http://dx.doi.org/10.1093/nar/gkg718
18. Lin, T., L. Meng, Y. Li, and R.Y. Tsai. 2010. Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res. 70:9444-9452. http://dx.doi.org/10.1158/0008-5472.CAN-10-2159
19. Liu, S.J., Z.W. Cai, Y.J. Liu, M.Y. Dong, L.Q. Sun, G.F. Hu, Y.Y. Wei, and W.D. Lao. 2004. Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies. World J. Gastroenterol. 10: 1246-1249.
20. Liu, L., S.M. Bailey, M. Okuka, P. Muñoz, C. Li, L. Zhou, C. Wu, E. Czerwiec, L. Sandler, A. Seyfang, et al. 2007. Telomere lengthening early in development. Nat. Cell Biol. 9:1436-1441. http://dx.doi.org/10.1038/ncb1664
21. Martínez, P., M. Thanasoula, P. Muñoz, C. Liao, A. Tejera, C. McNees, J.M. Flores, O. Fernández-Capetillo, M. Tarsounas, and M.A. Blasco. 2009. Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev. 23:2060-2075. http://dx.doi.org/10.1101/gad.543509
22. Meng, L., H. Yasumoto, and R.Y. Tsai. 2006. Multiple controls regulate nucleostemin partitioning between nucleolus and nucleoplasm. J. Cell Sci. 119:5124-5136. http://dx.doi.org/10.1242/jcs.03292
23. Meng, L., J.K. Hsu, Q. Zhu, T. Lin, and R.Y. Tsai. 2011. Nucleostemin inhibits TRF1 dimerization and shortens its dynamic association with the telomere. J. Cell Sci. 124:3706-3714. http://dx.doi.org/10.1242/jcs.089672
24. Nabetani, A., O. Yokoyama, and F. Ishikawa. 2004. Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. J. Biol. Chem. 279:25849-25857. http://dx.doi.org/10.1074/jbc.M312652200
25. Nomura, J., M. Maruyama, M. Katano, H. Kato, J. Zhang, S. Masui, Y. Mizuno, Y. Okazaki, M. Nishimoto, and A. Okuda. 2009. Differential requirement for nucleostemin in embryonic stem cell and neural stem cell viability. Stem Cells. 27:1066-1076. http://dx.doi.org/10.1002/stem.44
26. Ohmura, M., K. Naka, T. Hoshii, T. Muraguchi, H. Shugo, A. Tamase, N. Uema, T. Ooshio, F. Arai, K. Takubo, et al. 2008. Identification of stem cells during prepubertal spermatogenesis via monitoring of nucleostemin promoter activity. Stem Cells. 26:3237-3246. http://dx.doi.org/10.1634/stemcells.2008-0506
27. Potts, P.R., and H. Yu. 2005. Human MMS21/NSE2 is a SUMO ligase required for DNA repair. Mol. Cell. Biol. 25:7021-7032. http://dx.doi.org/10.1128/MCB.25.16.7021-7032.2005
28. Potts, P.R., and H. Yu. 2007. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat. Struct. Mol. Biol. 14:581-590. http://dx.doi.org/10.1038/nsmb1259
29. Shay, J.W., and S. Bacchetti. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer. 33:787-791. http://dx.doi.org/10.1016/S0959-8049(97) 00062-2
30. Shay, J.W., Y. Zou, E. Hiyama, and W.E. Wright. 2001. Telomerase and cancer. Hum. Mol. Genet. 10:677-685. http://dx.doi.org/10.1093/hmg/10.7.677
31. Songyang, Z., and D. Liu. 2006. Inside the mammalian telomere interactome: regulation and regulatory activities of telomeres. Crit. Rev. Eukaryot. Gene Expr. 16:103-118.
32. Tsai, R.Y. 2009. Nucleolar modulation of TRF1: a dynamic way to regulate telomere and cell cycle by nucleostemin and GNL3L. Cell Cycle. 8: 2912-2916.
33. Tsai, R.Y., and R.D. McKay. 2002. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev. 16:2991-3003. http://dx.doi.org/10.1101/gad.55671
34. Tsai, R.Y., and R.D. McKay. 2005. A multistep, GTP-driven mechanism controlling the dynamic cycling of nucleostemin. J. Cell Biol. 168:179-184. http://dx.doi.org/10.1083/jcb.200409053
35. Tsai, R.Y., and L. Meng. 2009. Nucleostemin: a latecomer with new tricks. Int. J. Biochem. Cell Biol. 41:2122-2124. http://dx.doi.org/10.1016/j.biocel.2009.05.020
36. van Steensel, B., and T. de Lange. 1997. Control of telomere length by the human telomeric protein TRF1. Nature. 385:740-743. http://dx.doi.org/10.1038/385740a0
37. van Steensel, B., A. Smogorzewska, and T. de Lange. 1998. TRF2 protects human telomeres from end-to-end fusions. Cell. 92:401-413. http://dx.doi.org/10.1016/S0092-8674(00)80932-0
38. Wu, G., W.H. Lee, and P.L. Chen. 2000. NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J. Biol. Chem. 275:30618-30622. http://dx.doi.org/10.1074/jbc.C000390200
39. Wu, G., X. Jiang, W.H. Lee, and P.L. Chen. 2003. Assembly of functional ALTassociated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res. 63:2589-2595.
40. Yeager, T.R., A.A. Neumann, A. Englezou, L.I. Huschtscha, J.R. Noble, and R.R. Reddel. 1999. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 59:4175-4179.
41. Yoon, H.J., I.Y. Choi, M.R. Kang, S.S. Kim, M.T. Muller, J.R. Spitzner, and I.K. Chung. 1998. DNA topoisomerase II cleavage of telomeres in vitro and in vivo. Biochim. Biophys. Acta. 1395:110-120.
42. Yu, J., J. Lan, C. Wang, Q. Wu, Y. Zhu, X. Lai, J. Sun, C. Jin, and H. Huang. 2010. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells. Cancer Lett. 291:177-186. http://dx.doi.org/10.1016/j.canlet.2009.10.009
43. Zhang, P., S.L. Chan, W. Fu, M. Mendoza, and M.P. Mattson. 2003. TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein-binding ability. FASEB J. 17:767-769.
44. Zhou, X.Z., K. Perrem, and K.P. Lu. 2003. Role of Pin2/TRF1 in telomere maintenance and cell cycle control. J. Cell. Biochem. 89:19-37. http://dx.doi.org/10.1002/jcb.10496
45. Zhu, X.D., B. Küster, M. Mann, J.H. Petrini, and T. de Lange. 2000. Cell-cycleregulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat. Genet. 25:347-352. http://dx.doi.org/10.1038/77139
46. Zhu, Q., H. Yasumoto, and R.Y. Tsai. 2006. Nucleostemin delays cellular senescence and negatively regulates TRF1 protein stability. Mol. Cell. Biol. 26:9279-9290. http://dx.doi.org/10.1128/MCB.00724-06
47. Zhu, Q., L. Meng, J.K. Hsu, T. Lin, J. Teishima, and R.Y. Tsai. 2009. GNL3L stabilizes the TRF1 complex and promotes mitotic transition. J. Cell Biol. 185:827-839. http://dx.doi.org/10.1083/jcb.200812121